Data on Pfizer, BioNTech COVID-19 Vaccine Candidate Published

Peer-reviewed preliminary data from Pfizer’s and BioNTech’s U.S. phase 1/2 trial of its COVID-19 vaccine candidate BNT162b1 were released yesterday, confirming findings previously released by the companies in early July.

A second 30-mcg dose of the vaccine generated neutralizing antibodies at levels 2.8 times those seen in the plasma of recovered patients, and the levels continued to increase up to 4.6 times higher than those seen in convalescent plasma 14 days after the second dose, according to the data published in the journal Nature.